FindTrial
Sign In

Whether high-risk features (HRFs) on the recurrence or microsatellite instability (MSI) status are predictive markers for adjuvant chemotherapy (ACT) in patients with stage II colon cancer is uncertain. This study aimed to examine the impact of HRFs and MSI on the prediction of the benefits of ACT in patients with stage II colon cancer. This multi-center retrospective study included 1801 patients with resected stage II colon cancer diagnosed at 17 university-affiliated hospitals between January 2010 and December 2017.

Microsatellite instability and high risk factors in decision making for adjuvant chemotherapy in stage II colon cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0009579
Enrollment
1300
Registered
2024-06-28
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Keimyung University Dongsan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with resected stage II colon adenocarcinoma

Exclusion criteria

Exclusion criteria: synchronous or previous malignancies, R1 or R2 resection, irinotecan-based ACT, or targeted therapy

Design outcomes

Primary

MeasureTime frame
5-year survival rate—

Secondary

MeasureTime frame
patient characteristics, pathologic outcomes—

Countries

Korea, Republic of

Contacts

Public ContactSungUk Bae

Keimyung University Dongsan Hospital

sabiston0000@hanmail.net+82-53-258-4708

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026